Develops telitacicept, a drug candidate for people with autoimmune diseases such as generalized myasthenia gravis and Sjögren’s disease.
10-K for FY2025, filed Mar 30, 2026
10-Q for Q3 FY2026, filed Oct 30, 2026
−$86.7MView ↗
8-K, filed Nov 12, 2026
RC298 is currently in IND-enabling development, with an IND submission in China anticipated in the first half of 2027. RemeGen will…View ↗
From blood cancer to autoimmunity
The earlier report centers on engineered stem-cell treatments for blood cancers; the latest centers on telitacicept for autoimmune diseases and says the prior clinical and manufacturing operations were wound down.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 30, 2026
Loading...